Skip to Content

Atripla Bristol-Myers Squibb Company / Gilead Sciences, Inc. - Treatment for HIV-1 Infection

Atripla is a once-daily single tablet regimen combining the non-nucleoside reverse transcriptase inhibitor Sustiva (efavirenz), and the nucleoside reverse transcriptase inhibitors Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate). Atripla is indicated as a stand-alone therapy or in combination with other antiretrovirals for the treatment of HIV-1 infection in adults.

Posted: July 2006

Related Articles:

Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate) FDA Approval History